Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01916733
Other study ID # M12-172
Secondary ID UVM Medical Grou
Status Completed
Phase N/A
First received July 30, 2013
Last updated October 24, 2016
Start date January 2013
Est. completion date June 2016

Study information

Verified date October 2016
Source University of Vermont Medical Center
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The aim of this study is to examine the effect of moderate glucose (blood sugar) control in diabetic and non-diabetic patients undergoing leg bypass surgery (LEB) or open abdominal aortic aneurysm (AAA) repair. We hypothesize that use of Fletcher Allen Health Care's current insulin infusion strategy will result in improved blood sugar control which will translate into decreased postoperative morbidity (fewer complications) and better long term outcomes when compared to patient outcomes at other institutions which utilize other blood sugar management strategies.


Description:

We plan a concurrent, matched cohort study of moderate postoperative glucose control in patients undergoing leg bypass or open AAA repair. Consecutive patients undergoing elective open AAA repair or leg bypass will be enrolled over a two year period. A population of de-identified patients from other institutions in the region matched for medical problems who did not receive an insulin infusion will be used as a control group.

Continuous intravenous insulin protocol The insulin infusion strategy is local standard of care for control of postoperative hyperglycemia after leg bypass surgery. Blood glucose monitoring is standard after open AAA surgery but the method of glucose control could range from sliding scale insulin to the use of an insulin infusion.

Diabetic and non-diabetic patients will be placed on the existing Fletcher Allen Health Care standardized algorithm of continuous IV insulin immediately after surgery and continued for 72 hours. The insulin infusion will be initiated if/ when the finger stick blood glucose is greater than or equal to 120 mg/dL, with a target titration goal between 80-150 mg/dL. The insulin infusion will be adjusted based on a defined algorithm in use at Fletcher Allen Health Care.

Primary outcome measures:

1. Glycemic control as measured by mean daily glucose levels and mean daily glucose excursions. We will look at the patients' finger-stick records and record the time spent at goal glucose levels, 80 to 150 mg/dL.

2. Surgical site infection (SSI) in-hospital will be defined according to the Centers for Disease Control definition16 as an infection that occurs within 30 days after the operative procedure and involves only skin and subcutaneous tissue of the infection and includes one of the following:

1. purulent drainage from superficial incision

2. organisms isolated from an aseptically obtained culture of fluid or tissue from the superficial incision

3. at least one of the following signs or symptoms of infection: pain or tenderness, localized swelling, redness, or heat and the incision is deliberately opened by the surgeon, and is culture positive or not cultured. Culture negative does not meet this criterion.

4. Diagnosis of superficial incisional SSI by the surgeon or attending. . 3. Surgical site infection at 30 days.

Secondary outcome measures:

1. Moderate to severe hypoglycemic or hyperglycemic events as defined by moderate hypoglycemic event as <66 mg/dl and severe hypoglycemic event as <50 mg/dl and moderate hyperglycemic event as >250 mg/dl and severe hyperglycemic event as >500 mg/dl.

2. Composite cardiac complications: myocardial infarction, congestive heart failure and clinically significant arrhythmias within 30 days of surgery,

3. Hospital length of stay, re-admission and total costs of the hospitalization. Cost data will be obtained through Fletcher Allen Health Care administrative data. At the patient's 4 week follow up they will be asked if since their discharge have they had any health related visits; if so what type and for anything possibly related to the surgical procedure obtain the participants permission (in writing) to gather that data from the other provider.


Recruitment information / eligibility

Status Completed
Enrollment 89
Est. completion date June 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria:

- Consecutive patients, all patients on the vascular service undergoing elective open AAA repair or infrainguinal LEB for claudication or critical limb ischemia will be approached and given the choice to participate in or to decline the study. Diabetic and non-diabetic.

Exclusion Criteria:

- Patients with purely acute limb ischemia will be excluded. Emergency operations including ruptured AAA repairs will be excluded. Also patients on a preoperative insulin infusion will be excluded.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Intervention

Drug:
standard insulin protocol post-op (continuous IV insulin)
concurrent, matched cohort study of moderate postoperative glucose control in patients undergoing LEB or open AAA repair.Propensity score matching is a statistical method used to reduce the confounding effects of covariates in an observational (non-randomized) study. In practice we will select a number of variables that impact wound infection; age, gender, diabetic and non-diabetic populations, renal insufficiency (defined at creatinine =1.8) and indication for surgery (claudication or critical limb ischemia with rest pain or tissue loss or open AAA repair); and chose a group of patients in the Vascular Study Group matched for these variables who have not been treated with an insulin infusion). Consecutive patients undergoing elective open AAA repair or infrainguinal LEB for claudication and critical limb ischemia will be invited to enroll in the study.

Locations

Country Name City State
United States Fletcher Allen Health Care Burlington Vermont

Sponsors (1)

Lead Sponsor Collaborator
University of Vermont Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary glycemic control 1. Glycemic control as measured by mean daily glucose levels and mean daily glucose excursions. We will look at the patients' finger-stick records and record the time spent at goal glucose levels, 80 to 150 mg/dL. during intial hospital stay which is an average of 3 to 7 days No
Primary surgical site infection Surgical site infection (SSI) in-hospital will be defined according to the Centers for Disease Control definition16 as an infection that occurs within 30 days after the operative procedure and involves only skin and subcutaneous tissue of the infection and includes one of the following:
purulent drainage from superficial incision
organisms isolated from an aseptically obtained culture of fluid or tissue from the superficial incision
at least one of the following signs or symptoms of infection: pain or tenderness, localized swelling, redness, or heat and the incision is deliberately opened by the surgeon, and is culture positive or not cultured. Culture negative does not meet this criterion.
Diagnosis of superficial incisional SSI by the surgeon or attending.
30 days No
Secondary hypo and hyper glycemic events . Moderate to severe hypoglycemic or hyperglycemic events as defined by moderate hypoglycemic event as <66 mg/dl and severe hypoglycemic event as <50 mg/dl and moderate hyperglycemic event as >250 mg/dl and severe hyperglycemic event as >500 mg/dl. during initial hospital stay avg 3 to 7 days No
Secondary cardiac complications Composite cardiac complications: myocardial infarction, congestive heart failure and clinically significant arrhythmias within 30 days of surgery 30 days No
Secondary length of stay Hospital length of stay initial hospitalization avg 3 to 7 days No
Secondary re-admission At the patient's 4 week follow-up they will be asked if since their discharge have they had any health related visits; if so what type and for anything possibly related to surgical procedure; will obtain participant's permission (in writing) to gather data from other provider. at 4 week follow-up No
Secondary Costs Cost data will be obtained through Fletcher Allen administrative data. 30 days No
See also
  Status Clinical Trial Phase
Completed NCT06309654 - Home-Based Circuit Training in Overweight/Obese Older Adult Patients With Knee Osteoarthritis and Type 2 Diabetes N/A
Active, not recruiting NCT05460884 - Effects of Seaweed Extract on Postprandial Response to White Bread N/A
Completed NCT00576394 - Aggressive Versus Moderate Glycemic Control in Diabetic Coronary Bypass Patients Phase 1
Recruiting NCT05777746 - The Effect of an Online Plant-Based Dietary Program on Cardiovascular Risk Factors in Persons With Type 2 Diabetes Mellitus: A Randomized Controlled Trial N/A
Completed NCT00898534 - Effect of Immediate Hemoglobin A1c on Glycemic Control in Children With Type I Diabetes Mellitus Phase 4
Recruiting NCT05115682 - Circadian Rhythm and Metabolic Effects of Exercise N/A
Completed NCT04994327 - Bread Replacement - Facing the Challenge to Improve Its Quality for Better Metabolic Health N/A
Terminated NCT01549964 - Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes Phase 3
Recruiting NCT04332393 - Metformin to Treat Corticosteroids-induced Hyperglycemia Phase 4
Recruiting NCT04821752 - Environmental Toxicants Avoidance Study N/A
Completed NCT06217679 - Comparing the Effects of Different Types of Exercise on Glucose Handling N/A
Completed NCT00821665 - Blood Glucose Homeostasis in Type 2 Diabetes: the Effects of Saccharose N/A
Terminated NCT04171648 - Effect of Dry Roasted Peanuts and Boiled Peanuts on Glycemic Control N/A
Completed NCT05279183 - Assessment of Reward Responses to Erythritol Using Flavor Preference Learning N/A
Completed NCT05166200 - Glycemic Response in Adults With Type 2 Diabetes N/A
Not yet recruiting NCT05644717 - Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD Phase 4
Active, not recruiting NCT00283972 - LAP-BAND Observational Cohort Phase 4
Completed NCT00460499 - Improving Outcomes In Diabetic Patients During CABG Surgery By Optimizing Glycemic Control Phase 1
Completed NCT00848315 - Diabetes Management in Low-Income Hispanic Patients Phase 2
Completed NCT03983499 - Latinos Understanding the Need for Adherence in Diabetes N/A